Journal
ANGIOLOGY
Volume 72, Issue 2, Pages 122-130Publisher
SAGE PUBLICATIONS INC
DOI: 10.1177/0003319720952284
Keywords
COVID-19; angiotensin-converting enzyme 2; coronavirus; renin-angiotensin system; spike protein
Categories
Ask authors/readers for more resources
This review examines the role of coronavirus spike protein and ACE2 receptor in infection, and discusses the therapeutic effect of inhibiting ACE2, providing insights for finding effective treatment targets in research.
With the global expansion of coronavirus disease 2019 (COVID-19) and the declaration of its outbreak as a Public Health Emergency of International Concern by the World Health Organization, there is an urgent need for vaccines and medicines to prevent and treat COVID-19. The responsible pathogen for the disease is the newly severe acute respiratory syndrome coronavirus (SARS-CoV) 2 belonging to the same family of viruses SARS-CoV and Middle East respiratory syndrome coronavirus that originally are zoonotic and have been associated with severe illness during the outbreaks in 2003 and 2012, respectively. The virulence of coronavirus strains is mainly associated with variations in surface proteins mediating cellular entry of the virus, which can help in finding effective therapeutic targets. In this review, we seek evidence showing the role of coronavirus spike protein (S-protein) and its potential cellular receptor, angiotensin-converting enzyme 2 (ACE2), during infection of coronaviruses, including the newly SARS-CoV-2 and its similar strain SARS-CoV. This review also discusses the therapeutic effect of inhibiting the renin-angiotensin system cascade, a target of ACE2, in patients having coronavirus with cardiovascular disease.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available